The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
Clinical trial NCT05523089 · COMPLETED
Trial details
- NCT number
- NCT05523089
- Sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-09
- Primary completion
- 2023-07-17
- Enrollment
- 59
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.